CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 578 enrolled
Drug / intervention
AVERTdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01976299
NCT01976299N/ACompleted
CompareCT.gov

AVERT™ Clinical Trial

Osprey Medical, Inc·interventional·Posted Nov 5, 2013·Updated Feb 28, 2017

In Brief

A clinical study evaluating AVERT for Contrast Induced Nephropathy (CIN). Completed, enrolled 578 participants across 39 sites in 3 countries.

Detailed Summary

The Osprey Medical AVERT System is indicated to reduce contrast media (CM) exposure to the kidneys during percutaneous coronary procedures thereby reducing the risk of contrast induced nephropathy (CIN).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsContrast Induced Nephropathy (CIN)
CountriesAustralia, New Zealand, United States
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 5, 2013
Enrollment StartDec 1, 2013
Primary CompletionJul 1, 2015
Study CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 12.7 years ago

Interventions

AVERTdevice